William Mu
University of California, Los Angeles
4 Papers
4 Citations
William Mu is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Medicine & Systemic inflammation. The author has an hindex of 2, co-authored 3 publications.
Chat about Author
Papers
Primary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody Responses.
F. Javier Ibarrondo,Christian Hofmann,Jonathan Fulcher,David Goodman-Meza,William Mu,Mary Ann Hausner,Ayub Ali,Arumugam Balamurugan,Ellie Taus,Julie Elliott,Paul Krogstad,Nicole H. Tobin,Kathie G Ferbas,Scott G. Kitchen,Grace M. Aldrovandi,Anne W. Rimoin,Otto O. Yang +16 more
TL;DR: In this paper, a longitudinal assessment of vaccinees with and without prior SARS-CoV-2 infection using quantitative enzyme-linked immunosorbent assay (ELISA) of anti-RBD antibodies was conducted.
74
Apolipoprotein A-I mimetics attenuate macrophage activation in chronic treated HIV
William Mu,Madhav Sharma,Rachel Heymans,Eleni Ritou,Valerie Rezek,Philip Hamid,Athanasios Kossyvakis,Shubhendu Sen Roy,Victor Grijalva,Arnab Chattopadhyay,Jeremy Papesh,David Meriwether,Scott G. Kitchen,Alan M. Fogelman,Srinivasa T. Reddy,Theodoros Kelesidis +15 more
TL;DR: Given that gut barrier dysfunction and macrophage activation are contributors to comorbidities like cardiovascular disease in HIV, apoA-I mimetics should be tested as therapy for morbidity in chronic treated HIV.
14
ApoA-I mimetics favorably impact cyclooxygenase 2 and bioactive lipids that may contribute to cardiometabolic syndrome in chronic treated HIV.
M. Daskou,M. Sharma,William Mu,Rachel Heymans,Eleni Ritou,Valerie Rezek,Philip Hamid,Athanasios Kossyvakis,Shubhendu Sen Roy,Victor Grijalva,Arnab Chattopadhyay,Jeremy Papesh,David Meriwether,Scott G. Kitchen,Alan M. Fogelman,Srinu T Reddy,Theodoros Kelesidis +16 more
TL;DR: In this paper, the authors investigated whether apolipoprotein A-I mimetic peptides 4F and 6F can reduce blood and gut bioactive lipids, proinflammatory effects of endotoxin (LPS) and aberrant activation of cyclooxygenase 2 (COX-2) as instigators of increased risk for cardiometabolic disease in chronic treated HIV.
6
ApoA-I mimetics reduce systemic and gut inflammation in chronic treated HIV
M. Daskou,William Mu,Madhav Sharma,Hariclea Vasilopoulos,Rachel Heymans,Eleni Ritou,Valerie Rezek,Philip Hamid,Athanasios Kossyvakis,Shubhendu Sen Roy,Victor Grijalva,Arnab Chattopadhyay,Scott G. Kitchen,Alan M. Fogelman,Srinivasa T. Reddy,Theodoros Kelesidis +15 more
TL;DR: Preclinical data suggest that apoA-I mimetic peptides provide a novel therapeutic strategy that can target increased protein levels of ADAM17 and its sheddase activity that contribute to intestinal and systemic inflammation in treated HIV.